Detalhe da pesquisa
1.
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl Lung Cancer Res
; 11(11): 2216-2229, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519016
2.
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.
Oncogenesis
; 10(11): 77, 2021 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775465